EPO Patents = 3

Forward Citations = 76

Loading Chart...

3 inventors (with patents filed for the assignee):

Ola Winqvist (6 out of 29 patents)

Magnus Thörn (5 out of 10 patents)

Magnus Thöm (1 out of 1 patent)

6 patents: Sort by Forward Citations

1. 8709404 - Immunotherapy in cancer treatment (2014-04-29),

2. 8211425 - Method for treating disseminated cancer (2012-07-03),

3. 8211424 - Method for treating malignant melanoma (2012-07-03),

4. 8206702 - Method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with cancer (2012-06-26),

5. 8101173 - Method for treating urinary bladder cancer (2012-01-24),

6. 8007785 - Method for treating colon cancer with tumour-reactive T-lymphocytes (2011-08-30),

Sentoclone International Ab is a leading biotechnology company specializing in innovative gene editing technologies. With a strong focus on precision medicine, our mission is to develop personalized therapies for a wide range of diseases. We offer cutting-edge solutions for genetic engineering and cell therapy, enabling researchers and clinicians to unlock the potential of gene therapy in healthcare.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

6 Patents

#124 in Stockholm

#890 in Sweden

Stockholm, Sweden

Sentoclone International Ab

Forward Citations = 76

3 inventors:

Ola Winqvist (6 out of 29 patents)

Magnus Thörn (5 out of 10 patents)

Magnus Thöm (1 out of 1 patent)

Please report any incorrect information to support@idiyas.com

3 patents (EPO):

Please report any incorrect information to support@idiyas.com